由BMS-284756筛选出的金黄色葡萄球菌突变体。
Staphylococcus aureus mutants selected by BMS-284756.
作者信息
Discotto L F, Lawrence L E, Denbleyker K L, Barrett J F
机构信息
Bristol-Myers Squibb Pharmaceutical Research Institute, Infectious Diseases, Department of Microbiology, Wallingford, Connecticut 06492, USA.
出版信息
Antimicrob Agents Chemother. 2001 Nov;45(11):3273-5. doi: 10.1128/AAC.45.11.3273-3275.2001.
Abstract
BMS-284756, a novel des-fluoro(6)-quinolone, was used to select for in vitro mutants of Staphylococcus aureus ISP794. Step mutants were obtained, and the quinolone resistance-determining regions of four target genes, gyrA, gyrB, grlA, and grlB, were sequenced. The data suggest that DNA gyrase is the primary target for BMS-284756 in S. aureus.
摘要
新型去氟（6）-喹诺酮BMS-284756用于筛选金黄色葡萄球菌ISP794的体外突变体。获得了逐步突变体，并对四个靶基因gyrA、gyrB、grlA和grlB的喹诺酮耐药决定区进行了测序。数据表明，DNA回旋酶是BMS-284756在金黄色葡萄球菌中的主要靶点。
相似文献
1
Staphylococcus aureus mutants selected by BMS-284756.
Antimicrob Agents Chemother. 2001 Nov;45(11):3273-5. doi: 10.1128/AAC.45.11.3273-3275.2001.
2
3
Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
Int J Antimicrob Agents. 2005 Apr;25(4):334-7. doi: 10.1016/j.ijantimicag.2004.11.013.
4
Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
Antimicrob Agents Chemother. 2002 Aug;46(8):2498-506. doi: 10.1128/AAC.46.8.2498-2506.2002.
5
Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.
Antimicrob Agents Chemother. 2002 Apr;46(4):1119-21. doi: 10.1128/AAC.46.4.1119-1121.2002.
6
Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus.
Chemotherapy. 2010;56(2):153-7. doi: 10.1159/000313529. Epub 2010 Apr 21.
7
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
Antimicrob Agents Chemother. 2002 Nov;46(11):3370-80. doi: 10.1128/AAC.46.11.3370-3380.2002.
8
Evaluation of a high-density oligonucleotide array for characterization of grlA, grlB, gyrA and gyrB mutations in fluoroquinolone resistant Staphylococcus aureus isolates.
J Microbiol Methods. 2005 Feb;60(2):275-9. doi: 10.1016/j.mimet.2004.09.015.
9
Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.
Clin Microbiol Infect. 2002 Dec;8(12):781-90. doi: 10.1046/j.1469-0691.2002.00400.x.
10
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Mol Microbiol. 1994 Aug;13(4):641-53. doi: 10.1111/j.1365-2958.1994.tb00458.x.
引用本文的文献
1
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Antimicrob Agents Chemother. 2007 Jul;51(7):2445-53. doi: 10.1128/AAC.00158-07. Epub 2007 May 14.
2
The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
Antimicrob Agents Chemother. 2006 Nov;50(11):3568-79. doi: 10.1128/AAC.00641-06. Epub 2006 Aug 28.
3
Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
Antimicrob Agents Chemother. 2005 Aug;49(8):3325-33. doi: 10.1128/AAC.49.8.3325-3333.2005.
4
Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.
Antimicrob Agents Chemother. 2004 Aug;48(8):3024-7. doi: 10.1128/AAC.48.8.3024-3027.2004.
5
Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2003 Mar;47(3):1023-7. doi: 10.1128/AAC.47.3.1023-1027.2003.
6
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
Antimicrob Agents Chemother. 2002 Nov;46(11):3370-80. doi: 10.1128/AAC.46.11.3370-3380.2002.
7
Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
Antimicrob Agents Chemother. 2002 Aug;46(8):2498-506. doi: 10.1128/AAC.46.8.2498-2506.2002.
8
Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.
Antimicrob Agents Chemother. 2002 Apr;46(4):1119-21. doi: 10.1128/AAC.46.4.1119-1121.2002.
9
Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.
Antimicrob Agents Chemother. 2002 Jan;46(1):191-5. doi: 10.1128/AAC.46.1.191-195.2002.
本文引用的文献
1
Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.
Antimicrob Agents Chemother. 2001 Oct;45(10):2865-70. doi: 10.1128/AAC.45.10.2865-2870.2001.
2
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.
Antimicrob Agents Chemother. 2000 Dec;44(12):3351-6. doi: 10.1128/AAC.44.12.3351-3356.2000.
3
Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.
Antimicrob Agents Chemother. 2000 Dec;44(12):3344-50. doi: 10.1128/AAC.44.12.3344-3350.2000.
4
Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.
J Antimicrob Chemother. 1998 Jan;41(1):49-57. doi: 10.1093/jac/41.1.49.
5
Confirmation of protoplast fusion-derived linkages in Staphylococcus aureus by transformation with protoplast DNA.
J Bacteriol. 1983 Apr;154(1):406-12. doi: 10.1128/jb.154.1.406-412.1983.
6
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Antimicrob Agents Chemother. 1992 Oct;36(10):2108-17. doi: 10.1128/AAC.36.10.2108.
Zotero 插件